{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Balbach ML"],"funding":["NCI NIH HHS","National Comprehensive Cancer Network"],"pagination":["100306"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9010630"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(5)"],"pubmed_abstract":["The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously \"undruggable\" target. Here, we present the second reported case of de novo <i>KRAS</i> G12C-mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?"],"journal":["JTO clinical and research reports"],"pubmed_title":["De Novo <i>KRAS</i> G12C-Mutant SCLC: A Case Report."],"pmcid":["PMC9010630"],"funding_grant_id":["K12 CA090625","030763"],"pubmed_authors":["Eisenberg R","Balbach ML","Iams WT"],"additional_accession":[]},"is_claimable":false,"name":"De Novo <i>KRAS</i> G12C-Mutant SCLC: A Case Report.","description":"The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously \"undruggable\" target. Here, we present the second reported case of de novo <i>KRAS</i> G12C-mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-04T19:31:56.906Z","creation":"2025-02-19T02:58:41.347Z"},"accession":"S-EPMC9010630","cross_references":{"pubmed":["35434667"],"doi":["10.1016/j.jtocrr.2022.100306"]}}